“There’s an anecdotal report of someone who died after experiencing brain edema, which is a not uncommon side effect of [Aduhelm],” says Dr. Alexander, the FDA advisor who voted against approval. In the early months of the drug being marketed, at least four deaths were reported among treated patients.
